

- 22 Alpalhão M, Borges-Costa J, Filipe P. Psoriasis in HIV infection: an update. *Int J STD AIDS* 2019; **30**: 596–604.
- 23 Borghi A, Virgili A, Corazza M. Dermoscopy of inflammatory genital diseases: practical insights. *Dermatol Clin* 2018; **36**: 451–461.
- 24 Christophers E, Mrowietz U. Psoriasis. In Burgdorf WHC, Plewig G, Wolff HH, Landthaler M, eds. *Braun-Falco's Dermatology*, 3rd edn. Springer Verlag, Berlin, 2009: 506–526.
- 25 Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol* 2009; **61**: 451–485.
- 26 Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. American Academy of Dermatology. *J Am Acad Dermatol* 2009; **60**: 643–659.
- 27 Long CC, Finlay AY. The finger-tip unit—a new practical measure. *Clin Exp Dermatol* 1991; **16**: 444–447.
- 28 Zeichner J, Lebwohl M, Tangheiti E et al. Optimizing topical therapies for treating psoriasis: a consensus conference. *Cutis [serial Online]* 2010; **86**(3 Suppl): 5–31.
- 29 van de Kerkhof PCM. Therapeutic strategies: rotational therapy and combinations. *Clin Exp Dermatol* 2001; **26**: 356–361.
- 30 Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. *Acta Derm Venereol* 2011; **91**: 5–11.
- 31 Bonnetblanc J-M. Psoriasis. *Ann Dermatol Venereol* 2006; **133**: 298–299.
- 32 Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. *Br J Dermatol* 2006; **154**: 1155–1160.
- 33 Welsh BM, Berzins KN, Cook KA, Fairley CK. Management of common vulval conditions. *Med J Aust* 2003; **178**: 391–395.
- 34 Paulsen E, Korsholm L, Brandrup F. A double-blind, placebo controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. *J Eur Acad Dermatol Venereol* 2005; **19**: 326–331.
- 35 Ryan C, Menter A, Guenther L. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. *Br J Dermatol* 2018; **179**: 844–852.
- 36 AlMutairi N, Eassa BI. A randomized controlled ixekizumab vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis. *Expert Opin Biol Ther* 2021; **21**: 297–298.
- 37 Burlando M, Herzum A, Carmisciano L, Cozzani E, Parodi A. Biological therapy in genital psoriasis in women. *Dermatol Ther* 2020; **33**: e13110.
- 38 Hong JJ, Mosca ML, Haderl EK, Brownstone ND, Bhutani T, Liao WJ. Genital and inverse/intertriginous psoriasis: an updated review of therapies and recommendations for practical management. *Dermatol Ther (Heidelb)* 2021; **11**: 833–844.
- 39 Kalb RE, Bagel J, Korman NJ et al. National Psoriasis Foundation. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* 2009; **60**: 120.
- 40 Hashim PW, Chima M, Kim HJ. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. *J Am Acad Dermatol* 2020; **82**: 360–365.
- 41 Guglielmetti A, Conlledo R, Bedoya J, Ianiszewski F, Correa J. Inverse psoriasis involving genital skin folds: successful therapy with dapsone. *Dermatol Ther (Heidelb)* 2012; **2**: 15.
- 42 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. *J Am Acad Dermatol* 2008; **59**: 295–315.
- 43 Owczarek W, Walecka I, Lesiak A et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. *Adv Dermatol Allergol* 2020; **37**: 821.
- 44 Lambert J. Pruritus in female patients. *Biomed Res Int* 2014; **2014**: 541867.
- 45 Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. *J Dermatol* 2014; **41**: 205–212.
- 46 Moyal-Barracco M, Wendling J. Vulvar dermatosis. *Best Pract Res Clin Obstet Gynaecol* 2014; **28**: 946–958.
- 47 Chibnall R. Vulvar pruritus and lichen simplex chronicus. *Obstet Gynecol Clin N Am* 2017; **44**: 379–388.
- 48 Goldstein AT, Thaci D, Luger T. Topical calcineurin inhibitors for the treatment of vulvar dermatoses. *Eur J Obstet Reprod Biol* 2009; **146**: 22–29.
- 49 Virgili A, Minghetti S, Borghi A, Corazza M. Phototherapy for vulvar lichen simplex chronicus: an 'off-label use' of a comb light device. *Photodermatol Photoimmunol Photomed* 2014; **30**: 332–334.
- 50 Bacha T, Hammami H, Zauak A, Tanfous AB, Fenniche S. The use of 308-nm excimer lamp as a novel treatment for vulvar lichen simplex chronicus. *Dermatol Ther* 2019; **32**: e12906.
- 51 Li L, He S, Jiang J. Comparison of efficacy and safety of high-intensity focused ultrasound at different powers for patients with vulvar lichen simplex chronicus. *Int J Hyperthermia* 2021; **38**: 781–785.
- 52 Corazza M, Borghi A, Minghetti S, Toni G, Virgili A. Effectiveness of silk fabric underwear as an adjuvant tool in the management of vulvar lichen simplex chronicus: results of a double-blind randomized controlled trial. *Menopause* 2015; **22**: 850–856.
- 53 Halonen P, Jakobsson M, Heikinheimo O, Gissler M, Pukkala E. Incidence of lichen sclerosus and subsequent causes of death: a nationwide Finnish register study. *BJOG* 2020; **127**: 814–819.
- 54 Kirtschig G, Kuik DJ. A Dutch cohort study confirms familial occurrence of anogenital lichen sclerosus. *J Womens Health Care* 2014; **3**: 209.
- 55 Oyama N, Chan I, Neill SM et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. *Lancet* 2003; **362**: 118–123.
- 56 Meyrick-Thomas RH, Ridley CM, McGibbon DH, Black MM. Lichen sclerosus and autoimmunity – a study of 350 women. *Br J Dermatol* 1988; **118**: 41–46.
- 57 Wallace HJ. Lichen sclerosus et atrophicus. *Trans St Johns Hosp Dermatol Soc* 1971; **57**: 9–30.
- 58 Regauer S, Reich O. Early vulvar lichen sclerosus: a histological challenge. *Histopathology* 2005; **47**: 340–347.
- 59 Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. *JAMA Dermatol* 2015; **151**: 1061–1067.
- 60 Cooper SM, Ali I, Baldo M, Wojnarowska F. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. *Arch Dermatol* 2008; **144**: 1432–1435.
- 61 Kalowitz Bieber A, Steuer AB, Melnick LE, Wong PW, Keltz Pomeranz MK. Autoimmune and dermatologic conditions associated with lichen sclerosus. *J Am Acad Dermatol* 2021; **85**: 228–229.
- 62 Virgili A, Minghetti S, Borghi A, Corazza M. Long-term maintenance therapy for vulvar lichen sclerosus: the results of a randomized study comparing topical vitamin E with an emollient. *Eur J Dermatol* 2013; **23**: 189–194.
- 63 Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus (Review). *Cochrane Database Syst Rev* 2011: CD008240.
- 64 Lewis FM, Tatnall FM, Velangi SS et al. British association of dermatologists guidelines for the management of lichen sclerosus, 2018. *Br J Dermatol* 2018; **178**: 839–853.
- 65 Virgili A, Borghi A, Toni G, Minghetti S, Corazza M. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. *Br J Dermatol* 2014; **171**: 388–396.